At a glance
The rise of superbugs is a global health issue and one of the leading threats to human health today according to the World Health Organisation.
Our portfolio of new antibiotic therapies holds the potential to address the major threat to human health posed by drug resistant bacteria.
Our lead candidate RECCE®327 is designed as abroad-spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning) and other bacterial infections, including superbugs.
Recce Pharmaceuticals Ltd is currently in discussions with the US Food & Drug Administration (FDA) as it seeks approval to test its therapy in humans.